Catabasis and Duchenne Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory DMD Trial Read more
Candel Therapeutics Acquires Next-Generation Herpes Drug Development Platform and Manufacturing Expertise Read more
Galecto and PharmAkea merge to create strong clinical-stage company developing first-in-class therapeutics in fibrosis and cancer Read more
Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies Read more
Bicycle Therapeutics and Cancer Research UK to collaborate on development of new Bicycle immuno-oncology candidate, BT7401 Read more
Veristat Strengthens Its European Presence with the Acquisition of The Clinical Trial Company Read more